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Background: Nearly one-third of serous ovarian cancer (OVCA) patients will not respond to initial treatment with
surgery and chemotherapy and die within one year of diagnosis. If patients who are unlikely to respond to current
standard therapy can be identified up front, enhanced tumor analyses and treatment regimens could potentially be
offered. Using the Cancer Genome Atlas (TCGA) serous OVCA database, we previously identified a robust molecular
signature of 422-genes associated with chemo-response. Our objective was to test whether this signature is an
accurate and sensitive predictor of chemo-response in serous OVCA.
Methods: We first constructed prediction models to predict chemo-response using our previously described 422-
gene signature that was associated with response to treatment in serous OVCA. Performance of all prediction
models were measured with area under the curves (AUCs, a measure of the model’s accuracy) and their respective
confidence intervals (CIs). To optimize the prediction process, we determined which elements of the signature most
contributed to chemo-response prediction. All prediction models were replicated and validated using six publicly
available independent gene expression datasets.
Results: The 422-gene signature prediction models predicted chemo-response with AUCs of ~70 %. Optimization
of prediction models identified the 34 most important genes in chemo-response prediction. These 34-gene models
had improved performance, with AUCs approaching 80 %. Both 422-gene and 34-gene prediction models were
replicated and validated in six independent datasets.
Conclusions: These prediction models serve as the foundation for the future development and implementation of
a diagnostic tool to predict response to chemotherapy for serous OVCA patients.
Keywords: Ovarian cancer, Chemo-response, Prediction model, Data integration, Individualized treatmentBackground
Epithelial ovarian cancer (OVCA) has the highest mor-
tality rate of all gynecologic cancers [1]. The most com-
mon histological subtype of OVCA is serous [2]. The
majority of patients present with advanced disease at
diagnosis and, while some benefit from a treatment
combining cytoreductive surgery and chemotherapy [3],
nearly a third of patients with serous OVCA will not
respond to this initial treatment and die from disease
within one year after diagnosis [1, 4]. Despite significant
research directed at understanding the biology of OVCA* Correspondence: jesus-gonzalezbosquet@uiowa.edu
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(http://creativecommons.org/publicdomain/ze[5, 6], outcomes remain poor for a majority of patients,
particularly those who do not respond to initial chemo-
therapy. A major limitation is the lack of validated
biomarkers that can effectively predict response to
chemotherapy [7, 8].
Previous attempts to define predictors of response to
treatment have been limited by number of patients in-
cluded, mixture of histological types and stages, and lack of
validation in independent sets [9, 10]. In contrast, breast
cancer gene signatures have been identified that can accur-
ately predict recurrence [11] and chemotherapeutic
response [12, 13]. These signatures were subsequently vali-
dated in independent clinical studies [13–15]. For example,
one of these signatures, OncotypeDx, used 600 cases to cre-
ate an association model and validated it in an additionalle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Table 1 Clinical data from TCGA patients
CR IR p-value*
Number of Patients 292 158
Age (Avg.) 60 59.6 N.S.
Grade N.S.
Grade 1 4 1
Grade 2 35 18
Grade 3 246 135
Stage p < 0.01
Stage I 10 3
Stage II 19 1
Stage III 224 123
Stage IV 39 29
Surgical outcome N.S.
Optimal (<1 cm residual) 207 92
Suboptimal (>1 cm residual) 52 57
Optimal Treatment p < 0.001
Optimal (Surgery + 6 cycles) 179 66
Suboptimal 113 92
*Multivariable analysis of TCGA clinical variables: Only FIGO stage and optimal
treatment (including optimal surgery AND 6 cycles of platinum-based chemotherapy)
were independently associated with chemo-response in serous OVCA
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available test for OVCA to identify which patients will
respond to initial treatment [16].
In recently published studies using the Cancer Genome
Atlas (TCGA) serous OVCA database [17], we identified a
robust molecular signature associated with chemo-
response by integrating publicly available biological and
clinical data from 450 serous OVCA patients. This yielded
a 422-gene molecular signature that was replicated in five
independent gene expression experiments [18]. The
contributing data used to identify this signature included
gene expression, gene copy number alteration, gene muta-
tions, DNA methylation, and miRNA profiles, all of which
are available in TCGA dataset for serous OVCA. The
presence of a strong association between the 422-gene sig-
nature and chemo-response from our previous work,
though, does not imply that the signature also is predictive
of chemo-response [9].
Therefore, the main objective of the present study was
to determine the performance of the 422-gene signature
as a predictor of chemo-response in serous OVCA. We
also optimized and determined which of the elements of
the signature contributed more to all prediction models.
In this process, we identified a smaller set of 34 genes
(the “optimized” set) from the original 422 signature that
are predictive of response and that replicated the area
under the curve (AUC) of the original complete gene
set. Our data demonstrate that both the complete and
the optimized models are predictive of outcome and are
now replicated and validated in independent datasets.
Methods
Patients and data collection for prediction model
All data collection and processing, including the con-
senting process, were performed after approval by all
local institutional review boards and in accord with the
TCGA Human Subjects Protection and Data Access Pol-
icies, adopted by the National Cancer Institute (NCI)
and the National Human Genome Research Institute
(NHGRI).
Patients with serous OVCA in TCGA were utilized to
create a prediction model in the testing dataset, and were
divided into two categories: complete responders (CR) and
incomplete responders (IR). Clinical complete response
(CR) was defined as progression-free survival 6 months
after the first platinum-based treatment. In patients with in-
complete response (IR), the disease either not did respond
or progressed during treatment (refractory), or recurred
within 6 months of treatment completion (resistant) [4, 19].
Patients defined as IR in our study are also clinically re-
ferred to as ‘platinum-resistant’ [20], with direct implica-
tions for treatment and prognosis. In the TCGA dataset,
there were 292 patients classified as CR and 158 classified
as IR. Table 1 describes the clinical characteristics of thesepatients. Chemo-response was the most significant prog-
nostic factor for survival in multivariable analysis by Cox
proportional hazards regression (p-value < 10−14), and pa-
tients with IR had a significantly decreased median survival
compared to CR patients (Fig. 1) [18].
Gene signature and prediction analysis
We previously identified a 422-gene signature that is ro-
bustly associated with chemo-response [18]. To assess
predictive performance of this signature, we applied the
‘Classification for MicroArrays’ (CMA) to TCGA serous
OVCA data. CMA is a statistical tool designed to con-
struct and evaluate classifiers (or prediction models) de-
rived from microarray experiments using a large number
of standard methods [21] and the R environment for
statistical computing (www.r-project.org) [22].
Of the different methods available in the CMA package
[21] to perform the analysis, nine methods consistently
handle missing values, lower number of samples, and
compute AUCs without reporting any errors: random
forest [23], least absolute shrinkage and selection operator
(Lasso) [24], Elastic Net [24], prediction analysis for mi-
croarrays (PAM) [25], diagonal discriminant analysis [26],
partial least squares (PLS) [27], PLS - random forest [27],
penalized logistic regression [28], and PLS - logistic re-
gression [27]. We used these nine methods for the rest of
the study to compare the predictive performance of all of
the different datasets and for both the complete and opti-
mized models. Two other available methods, linear and
Fig. 1 Survivorship by chemo-response in serous OVCA TCGA data.
Chemo-response was the most significant factor in the multivariable
analysis for survival. Complete responders (CR) have a median survival
2 years greater than IR
Table 2 Publicly available GEO datasets of patients with serous
OVCA used for validation/replication of prediction models







90 37 MCC Marchion, 2011 [32]
Bild, 2006 [33]
GSE9891 185 55 Australia Tothill, 2008 [34]
GSE28739 20 30 Trinh Trinh, 2011 [36]
GSE17260 93 17 Yoshihara Yoshihara, 2010 [37]
GSE30161 32 23 Ferriss Ferriss, 2012 [35]
EMBL-EBI accession number
E-MTAB-386 64 41 Bentink Bentink, 2012 [38]
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discriminant analysis could not handle more variables
than subjects; neural networks was unstable/difficult to
tune and interpret; k-nearest neighbors and support vec-
tor machines could not tune and evaluate AUCs.
Initially, all 422 genes associated with chemo-response
in serous ovarian cancer [18] were utilized to construct
prediction models, termed 422-gene prediction models.
To assess how accurately the groups (CR and IR) were
predicted, and to avoid over-fitting, cross-validation was
used (internal validation of the classifier) [29]. The
predictive performance was computed with corrections
for TCGA batch-effect and to account for two other
variables independently associated with chemo-response
in serous OVCA (FIGO stage classification and optimal
treatment, Table 1) [10]. Sensitivity, specificity and AUC
of the predictor/classifier were also calculated. For each
of the AUC measurements, we also computed a 95 %
confidence interval (CI) to compare different models
and different methods of classification. To illustrate
the performance of the predictor in classifying chemo-
response, a receiver operating characteristic (ROC) curve
was generated. These analyses also facilitated compa-
rison of the performance of the predictor models across
independent serous OVCA datasets and assessed how
consistently the models predicted chemo-response
in OVCA patients based on sensitivity, specificity,
misclassification rate, and AUC. Finally, we identified
which patients were more likely to be misclassified and
the clinical characteristics that were associated with
misclassification.Selection of most informative genes of prediction models
We focused on the selection of informative genes, because
the composition of prediction models is paramount for their
performance [9]. The selection process was performed with
all available methods in the software package: two-sample t-
test; Welch modification of the t-test; Wilcoxon rank sum
test; F-test; Kruskal-Wallis test; “moderated” t and F test, re-
spectively, using the package ‘limma’ in R statistics; one-
step Recursive Feature Elimination (RFE) in combination
with the linear support vector machines (SVM); random
forest variable importance measure; least absolute shrink-
age and selection operator (or Lasso); the regularized re-
gression method or elastic net; component-wise boosting;
and ad-hoc “Golub” criterion [21]. Using the gene selection
tool, each gene was ranked depending on its relative im-
portance in prediction models. These genes were ordered
based on their rank and their relative ‘weight’ in the predic-
tion process, and the prediction model analysis was applied
by including only those genes that had been ranked at least
once (one ‘hit’) by each method. These models, containing
only the 34 selected and more informative genes, were
termed 34-gene prediction models and comprised the opti-
mized gene set as compared to the complete gene set.
Data retrieval for replication and validation analyses
Validation and replication of the prediction models was per-
formed using datasets in the Gene Expression Omnibus
(GEO) and the European Bioinformatics Institute, part of
the European Molecular Biology Laboratory (EMBL-EBI),
that contain gene expression paired with treatment response
data (Table 2). Databases were downloaded in their raw state
to maximize platform and annotation information, and then
data were normalized. Response to therapy variables were
coded to make outcomes comparable with TCGA: CR and
IR. Also, patients that underwent optimal debulking (with
largest residual disease of <1 cm) and completed six cycles
of platinum-based therapy were considered to have ‘optimal
treatment’. Lesser treatments were considered suboptimal.
Fig. 2 Area under the ROC curve (AUC) for the 422-gene prediction
models. a Box plot representations of the AUC for the complete model
by different methods. RF: Random forest; Lasso (least absolute shrinkage
and selection operator); Elastic Net; PAM: Prediction analysis for
microarrays; DDA: Diagonal discriminant analysis; PLS-LR: Partial
least squares - Logistic regression; PLR: Penalized logistic regression;
PLS: Partial least squares; PLS-RF: Partial least squares - Random forest.
b Prediction performance measured in AUC, with their respective
standard error, and confidence intervals (CI) by different methods using
all 422 genes. PAM: Prediction analysis for microarrays; PLS: Partial least
squares; Lasso: least absolute shrinkage and selection operator
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FIGO stage of disease were also significantly and independ-
ently associated with chemo-response in TCGA (Table 1).
Both clinical variables were collected, when available, and
assessed for association to chemo-response in these new
datasets in order to account for them in the prediction ana-
lysis. Also, batch-effect, if available, was accounted for to
correct for any bias, as was also performed in the initial pre-
diction model using the TCGA dataset.
Replication and validation analyses
Initially, we replicated the prediction analysis of all 422
genes associated with chemo-response, or the complete pre-
diction model, in all independent databases to assess how
accurately chemo-response was predicted. Cross-validation
was used for internal validation of the classifier, and predict-
ive performance was computed with the same methods de-
scribed for the TCGA dataset. Sensitivity, specificity, and
AUC were calculated. Databases that contained information
on all variables were later used for validation of the pre-
dictor/classifier of both the 422-gene and the 34-gene pre-
diction models.
Validation of the 422-gene prediction models from TCGA
data (the training set) and independent datasets (testing sets)
was performed using the ‘prediction’ tool of the CMA pack-
age. Only independent datasets with information on all vari-
ables were used as testing sets. Sensitivity, specificity and
AUC were used to measure the performance of the predic-
tion model. Validation of the optimized 34-gene prediction
models, including only the 34 most informative genes, was
also performed in those independent datasets with informa-
tion on all variables, and the same measures were used to
assess the performance of the classifier.
Software
Apart from the ‘Classification for MicroArrays’ (CMA)
utilized for the prediction analysis and already described,
other analyses (i.e., logistic regression, Cox regression,
Kaplan-Meier survival estimation), were performed
using R software for statistical computing and graphics
and utilizing Bioconductor packages as open source soft-
ware for bioinformatics (bioconductor.org). Differential
gene expression analysis was performed using Biometric
Research Branch (BRB) ArrayTools, an integrated pack-
age for visualization and statistical analysis that utilizes
Excel (Microsoft, Redmond, WA) as a front end, and
with tools developed in the R statistical system. BRB-
ArrayTools were developed by Dr. Richard Simon and
the BRB-ArrayTools development team. Associations of
the 34 most informative genes with survival were esti-
mated with a multivariate Cox regression model and re-
ported as hazard-ratios along with 95 % confidence
intervals, and likelihood ratio test was used to compare
models of survival, also within R environment.To identify biological processes and pathways over-
represented in the selected group of genes, we performed
pathway enrichment analyses with MetaCore 6.0 [30]
(GeneGo Inc., MI), an integrated knowledge-based plat-
form for pathway analysis of OMICs data and gene lists,
and other R-based tools, such as clusterProfiler [31],
which mines the KEGG database (Kyoto Encyclopedia of
Genes and Genomes, www.genome.jp/kegg).
Results
422-gene prediction model with all signature genes
Initially, we performed the prediction analysis of chemo-
response including all 422 genes of the signature, which
we refer to herein as the 422-gene prediction models.
Figure 2 summarizes the predictive performance of all
422-gene prediction models. Their performance resulted
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mances of the 422-gene prediction models were not ex-
plained by prediction models constructed only with
FIGO stage classification and optimal treatment, the
clinical variables that have been independently associ-
ated with chemo-response (mean AUC around 58 %,
Table 3).
Selection of the most informative genes and predictive
performance of the 34-gene prediction model
The variable selection process identified 105 different
genes to be relevant (i.e., at least one ‘hit’) in the predic-
tion model. Of those, only 34 genes had more than 10
hits with all methods of gene selection (at least one hit
per method): RHOT1, MYO7A, ZBTB10, MATK, ST18,
RPS23, GCNT1, DROSHA, NUAK1, CCPG1, PDGFD,
KLRAP1, MTAP, RNF13, THBS1, MLX, FAP, TIMP3,
PRSS1, SLC7A11, PRSS2, OLFML3, RPS20, MCM5,
POLE, STEAP4, LRRC8D, C10orf26 (WBP1L), ENTPD5,
SYNE1, DPT, COPZ2, TRIO, and PDPR. These were con-
sidered to be the most relevant genes for the construc-
tion of the model. A new prediction for chemo-response
was performed with these 34 genes, termed the opti-
mized 34-gene prediction models, with corrections for
batch-effect and clinical variables and using cross-
validation (Fig. 3). By selecting only those genes that
were most informative in prediction models and remov-
ing those that had little or no influence, the performance
of the signature in terms of AUC increased across the
board by 6–10 % regardless of the specific method.
The 34 selected genes for the optimized prediction
model were included in the initial 422-gene signature
through different modes: 27 presented differential gene
expression between CR and IR, 20 related to copy num-
ber variation between CR and IR (14 of them also had
differential gene expression), five were correlated with
genes with differential DNA methylation between CR
and IR, and seven were correlated with miRNAs with
different expression between CR and IR (Fig. 4). The
relative chromosomal position of the 34 selected genesTable 3 AUCs and their CI comparing the 422-gene prediction mod
PAM: Prediction analysis for microarrays; PLS: Partial least squares; Lasso: least abso
CI of clinical prediction model WITH significant overlap with TCGA 422-gene predictiand the spatial distribution are displayed in Fig. 5 in a
circular layout with matrix depiction of their relative ex-
pression (Table 4 has detailed information about these
34 genes). Multivariate analysis of survival using Cox
proportional hazards regression identified that six of the
34 genes were independently associated with survival
(Fig. 6).
Pathway enrichment analysis using both GeneGo and
clusterProfiler revealed that the 34 genes are particularly
relevant to protein absorption and metabolism and DNA
repair and replication (Table 5). Also, cytoskeletal re-
modeling and cell adhesion functions were significantly
represented in GeneGo (Table 5), consistent with path-
ways that are frequently implicated in response to ther-
apy and disease progression.
Replication of prediction models in independent datasets
After downloading the databases detailed in Table 2,
only cases of serous OVCA were selected, and the out-
come of interest (chemo-response) was coded to make
outcomes comparable with the initial TCGA data set:
CR and IR. Initially, we replicated the 422-gene predic-
tion models with cross-validation to avoid over-fitting.
Performance of prediction models were measured with
AUC (Table 6). AUCs of the prediction models in the in-
dependent validation datasets were comparable with the
testing set from the TCGA, with CIs overlapping the
testing set for almost all methods that contained infor-
mation from the full 422-gene signature (marked red in
Table 6) [32–35].
Unfortunately, all genes were not available in all plat-
forms from the independent datasets, and three independ-
ent datasets had incomplete gene information [36–38].
The performance of these incomplete datasets was inferior
to the TCGA classifier, with AUCs closer to 50 % (marked
green in Table 6; see also Additional file 1: Table S1 for
more details about classifier performance in relation to
sensitivity, specificity, and standard errors in all available
databases). Thus, the incomplete information in some of
the replication sets provided insight into how wellel and clinical prediction models
lute shrinkage and selection operator; NA: not available (not computable)
on model CI: in red
Fig. 3 AUC for 34-gene predictions models. AUCs and CIs for the predicting methods using the most relevant genes in the prediction model/
classifier: RF: Random forest; Lasso (least absolute shrinkage and selection operator); Elastic Net; PAM: Prediction analysis for microarrays; DDA:
Diagonal discriminant analysis; PLS-LR: Partial least squares - Logistic regression; PLR: Penalized logistic regression; PLS: Partial least squares; PLS-RF:
Partial least squares - Random forest
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were not available.
Validation of prediction models in independent datasets
Validation of 422-gene prediction models were per-
formed using TCGA data as the training set and inde-
pendent datasets that contained complete information
for all 422-genes as the testing sets. AUC and their CIs
were used to validate the performance of the TCGA
classifier in the three independent datasets with all gene
expression information (Table 7). CIs of the AUC in the
three different validation sets overlapped with the major-
ity of the CIs of TCGA testing set (marked red in
Table 7), validating the use of the 422-gene signature to
predict chemo-response.
Next, we validated TCGA 34-gene prediction models
in the same three independent datasets with all geneinformation, that also included all the most informative
34 genes selected from the training set. Analysis of
AUCs and CIs demonstrated that the optimized model
performed very well in these validations sets, with AUC
values ranging from 56 to 73 % and overlap of the ma-
jority of the CIs with the testing test (in red in Table 8).
However, the CIs were wider in the validation set than
in the testing set. For details about prediction models
performance in relation to sensitivity, specificity, and
standard deviation in all available databases see
Additional file 2: Table S2.
Clinical characteristics associated with misclassification in
prediction models
Additional file 1: Tables S1 and Additional file 2: Table
S2 list the misclassification rate for each of the predic-
tion models in all analyzed datasets. To assess whether
Fig. 4 Origin of 34 genes selected in the optimized prediction model. Initially, genes were included in the 422-gene signature because of their
differential gene expression (red), miRNA expression (pink), DNA methylation (blue), or copy number variation (green) between CR and IR. Some
genes had more than one biological difference
Fig. 5 Genomic position of 34 genes selected for the optimized prediction model. a The 34 most informative genes from the prediction model
and their chromosomal location: chr: number of the chromosome were the gene is located; start: of the gene position; length: of the gene in
base-pairs (bp). The human genome version was hg19. b Circular layout with matrix depiction of different biological variables. From external to internal:
Chromosome bands: circular representation of all chromosomes (centromere is in red); d Differential gene expression between incomplete and complete
responders (CR/IR; red is over-expressed, green is under-expressed); c Differential DNA methylation between CR and IR (CR/IR; blue is hypomethylated,
orange is hyper methylated); b Differential miRNA expression between CR and IR (CR/IR; red is over-expressed, grey is under-expressed); a Gene copy
number variation between CR and IR (copy gain is red, green is copy loss). The order of genes in a is the same as in b. Lines represent correlations between
different biological variables (for more details see Table 4)
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Table 4 Genomic information and reason for inclusion in the original 422-gene signature for the 34 genes selected in the prediction model
Annotation Expression Copy number DNA Methylation miRNA expression
Symbol Name Entrez-
ID








LRRC8D leucine rich repeat
containing 8 family,
member D
55144 1 90286572 115417 1.13
OLFML3 olfactomedin-like 3 56944 1 114522029 2846 0.76
DPT dermatopontin 1805 1 168664694 33748 0.9
FAP fibroblast activation
protein, alpha
2191 2 163027199 72846 0.7
RNF13 ring finger protein 13 11342 3 149530474 149451 Gain 3q22.1-q29 CRKRS 1.19
SLC7A11 solute carrier family 7,
(cationic amino acid
transporter, y + system)
member 11
23657 4 139085247 78256 Loss 4q13.3-q35.2
TRIO triple functional domain
(PTPRF interacting)
7204 5 14143828 365630 1.18 Gain 5p15.33-p13.1
DROSHA drosha, ribonuclease
type III
29102 5 31400601 131681 1.16 Gain 5p15.33-p13.1
RPS23 ribosomal protein S23 6228 5 81569138 5097 0.96 Loss 5q11.2-q21.1 UNQ9217 1.15 miR-22 0.8
SYNE1 spectrin repeat containing,
nuclear envelope 1





STEAP4 STEAP family member 4 79689 7 87905743 30466 SYNE1 0.82
PRSS1 protease, serine, 1 (trypsin 1) 5644 7 142457318 3609 1.32 Gain 7q32.1-q36.3
PRSS2 protease, serine, 2 (trypsin 2) 5645 7 142479907 1471 1.34 Gain 7q32.1-q36.3
ST18 suppression of tumorigenicity
18 (breast carcinoma) (zinc
finger protein)
9705 8 53023391 299048 0.97 Gain 8p11.21-q24.3
RPS20 ribosomal protein S20 6224 8 56980738 6402 Gain 8p11.21-q24.3 miR-135b 1.22
ZBTB10 zinc finger and BTB domain
containing 10
65986 8 81398447 36163 1.2 Gain 8p11.21-q24.3 miR-708 1.2
MTAP methylthioadenosine
phosphorylase




2650 9 79056581 65751 1.17
C10orf26 WBP1L - chromosome 10
open reading frame 26
54838 10 104503726 72295 0.87 No













Table 4 Genomic information and reason for inclusion in the original 422-gene signature for the 34 genes selected in the prediction model (Continued)
PDGFD platelet derived growth
factor D
80310 11 103777913 257114 0.76 No
KLRAP1 killer cell lectin-like receptor
subfamily A pseudogene 1
10748 12 10741076 11358 Gain 12p13.33-
p11.21
miR-22 0.8
NUAK1 NUAK family, SNF1-like kinase, 1 9891 12 106457124 76687 0.75 No
POLE polymerase (DNA directed),
epsilon
5426 12 133200347 63598 1.14 No
ENTPD5 ectonucleoside triphosphate
diphosphohydrolase 5
957 14 74433180 52846 1.13 No











55066 16 70147528 47656 1.04 Loss 16q12.2-q24.3
RHOT1 ras homolog gene family,
member T1
55288 17 30469472 83274 0.87 Gain 17p13.3-q21.2
MLX MAX-like protein X 6945 17 40719077 6144 0.88 No
COPZ2 coatomer protein complex,
subunit zeta 2
51226 17 46103532 11620 0.78 No
MATK megakaryocyte-associated
tyrosine kinase
4145 19 3777966 8449 0.93 No
TIMP3 TIMP metallopeptidase
inhibitor 3
7078 22 33196801 62227 0.7 Loss 22q11.22 miR-22 0.8
MCM5 minichromosome maintenance
complex component 5
4174 22 35796115 24380 1.19 Loss 22q11.22-
q13.33
In the Expression, Copy number, DNA methylation, and miRNA expression, only those with significant differential values between CR and IR were represented. Some genes had more than one biological difference
Copy number shows the chromosomal region (cytoband) that was significantly correlated with gene expression in the 422-gene signature. DNA Methylation and miRNA expression shows the initial variables that were













Fig. 6 Multivariate survival analysis of the 34 selected genes. a Table
with hazard-ratio (HR) or risk of death, with 95 % CIs and p-values for
each of the genes independently associated with survival. b Forest plot
of independently significant genes for survival. Blue boxes represent
hazard-ratios (HR), and lines are their CIs. HR = 1 is non-significant. HR < 1
has decreased risk of death; HR > 1 has increased risk of death. Overall
p-value of the survival model: p= 5.7×10−7
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cluded those patients at high risk of misclassification
and the clinical characteristics that are associated with
this misclassification. First, we identified those samples
that missed the true classification (either CR or IR) more
than 20 % of the time on average: 158 of 450 patients in
TCGA dataset. Next, we examined which baseline clinic
characteristics (e.g., grade, stage, optimal debulking)Table 5 Pathway enrichment analysis of the selected 34 genes cons
Cluster Profiler pathway enrichment analysis
KEGG ID Description
hsa03030 DNA replication




GeneGO pathway enrichment analysis
# Description
1 Cell adhesion_Chemokines and adhesion
2 Immune response_IL-12 signaling pathway
3 Cytoskeleton remodeling_Role of PDGFs in cell migration
4 Triacylglycerol metabolism p.2
5 Development_Thrombospondin-1 signaling
6 Cell cycle_Start of DNA replication in early S phase
7 Role of Tissue factor in cancer independent of coagulation prowere independently associated with misclassification
using a multivariable regression analysis. The only inde-
pendent variable associated with misclassification was
‘optimal treatment’ (p < 0.001), defined as treatment with
optimal cytoreductive surgery and 6 cycles of platinum-
based chemotherapy. Unfortunately, TCGA was not de-
signed to study chemo-response, and other variables that
may have affected the delivery of an optimal treatment
were not collected and thus could not be included in the
prediction models.
Discussion
Initial response to chemotherapy remains one of the
most significant prognostic markers for serous OVCA
patients. Identifying patients at high risk of chemoresis-
tance early in the course of treatment has the potential
to significantly alter clinical management, such as per-
forming in depth tumor sequencing, more frequent dis-
ease monitoring or exploration of additional therapeutic
options. Previous studies have focused in prediction
models that classify ovarian cancer patients in prognos-
tic groups [9, 10, 17]. While this is very valuable to clini-
cians and patients to assess the severity of the disease,
prognosticators have limited immediate clinical applica-
tion and they may not translate into effective therapeutic
strategies. The design of our study was aimed to have
immediate effect on treatment decisions. Using data
available in TCGA for serous OVCA, we previously
identified a 422-gene signature that is associated with
chemo-response [18]. However, in order to develop this




















3.89E-02 9.91E-02 Thrombospondin 1
4.43E-02 9.91E-02 MCM5
tease signaling 4.84E-02 9.91E-02 Thrombospondin 1
Table 6 Replication of 422-gene prediction models with different methods
ALL 422 GENES AVAILABLE
Training set Replication sets
TCGA: 422 genes Australia: 422 genes Ferriss: 422 genes MCC: 422 genes
AUC SE 95% CI AUC SE 95% CI AUC SE 95% CI AUC SE 95% CI
Random Forest 0.68 0.03 0.62, 0.73 0.67 0.03 0.61, 0.73 0.63 0.11 0.41, 0.85 0.54 0.04 0.46, 0.63
Lasso 0.72 0.03 0.67, 0.77 0.55 0.05 0.46, 0.64 0.65 0.08 0.49, 0.81 0.64 0.05 0.54, 0.74
Elastic Net 0.73 0.02 0.68, 0.77 0.58 0.04 0.50, 0.65 0.65 0.10 0.45, 0.85 0.64 0.04 0.56, 0.72
PAM 0.65 0.03 0.59, 0.71 0.69 0.04 0.62, 0.77 0.65 0.08 0.50, 0.81 0.49 0.06 0.38, 0.60
Diagonal Discriminant Analysis 0.67 0.03 0.62, 0.73 0.67 0.04 0.61, 0.74 0.57 0.10 0.38, 0.77 0.52 0.06 0.41, 0.64
PLS - Logistic regression 0.70 0.03 0.65, 0.75 0.67 0.04 0.60, 0.74 0.54 0.04 0.46, 0.62 0.60 0.05 0.49, 0.70
Penalized Logistic Regression 0.53 0.02 0.49, 0.58 0.56 0.04 0.48, 0.64 0.56 0.07 0.41, 0.70 0.56 0.07 0.43, 0.70
Partial Least Squares 0.70 0.03 0.65, 0.75 0.68 0.03 0.62, 0.74 0.60 0.08 0.44, 0.75 0.62 0.05 0.51, 0.72
PLS - Random Forest 0.67 0.02 0.63, 0.72 0.58 0.04 0.51, 0.66 0.51 0.07 0.37, 0.65 0.61 0.07 0.47, 0.75
MISSING SOME GENE INFORMATION FOR THE ANALYSIS
Yoshihara: 377 genes Bentink: 365 genes Trinh: 248 genes
AUC SE 95% CI AUC SE 95% CI AUC SE 95% CI
Random Forest 0.55 0.08 0.38, 0.71 0.45 0.04 0.37, 0.54 0.49 0.12 0.26, 0.72
Lasso 0.45 0.09 0.27, 0.62 0.48 0.05 0.38, 0.58 0.15 0.04 0.06, 0.24
Elastic Net 0.46 0.09 0.28, 0.63 0.50 0.04 0.41, 0.58 0.17 0.05 0.07, 0.26
PAM 0.53 0.09 0.35, 0.71 0.49 0.07 0.35, 0.63 0.00 0.00 0.00, 0.00
Diagonal Discriminant Analysis 0.51 0.09 0.34, 0.68 0.48 0.06 0.37, 0.59 0.00 0.00 0.00, 0.00
PLS - Logistic regression 0.48 0.09 0.31, 0.65 0.54 0.05 0.44, 0.64 0.00 0.00 0.00, 0.00
Penalized Logistic Regression 0.77 0.07 0.64, 0.90 0.63 0.06 0.52, 0.75 0.18 0.06 0.07, 0.28
Partial Least Squares 0.48 0.08 0.32, 0.63 0.55 0.05 0.45, 0.65 0.03 0.03 0.00, 0.07
PLS - Random Forest 0.59 0.09 0.43, 0.76 0.65 0.05 0.55, 0.76 0.05 0.05 0.00, 0.15
The table presents the results taking in consideration: 1) whether they were part of the training or replication set; 2) the number of genes available for analysis:
on top analyses including all 422 genes; on the bottom analyses where all genes were not available (and the number included)
CI of replication datasets with WIDE overlap with TCGA testing set CI: in red. CI of replication datasets with NO overlap with TCGA testing set CI: in green. AUC:
area under the ROC curve. CI: confidence intervals. SE: Standard Error. PAM: Prediction analysis for microarrays; PLS: Partial least squares; Lasso: least absolute
shrinkage and selection operator
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the performance and validation of the 422-gene and op-
timized 34-gene models using TCGA and six other data-
sets. Specifically, 422-gene prediction models in the
testing dataset (TCGA) presented AUCs around 70 %,
and 34-gene predictive models performed slightly better,
with AUCs above 70 %. This represents a significant im-
provement over current clinical estimations of complete
chemo-response, which are between 40 and 60 % [3],
setting the stage for the development of the 34-gene pre-
dictive model as a test to identify patients with serous
OVCA at high risk for treatment failure.Table 7 Validation of 422-gene prediction models in independent d
ALL 422 GENES AVAIL
Training set Valid
TCGA Austr
AUC 95% CI AUC
Random Forest 0.68 0.62, 0.73 0.63
Lasso 0.72 0.67, 0.77 0.57
Elastic Net 0.73 0.68, 0.77 0.57
PAM 0.65 0.59, 0.71 0.50
Diagonal Discriminant Analysis 0.67 0.62, 0.73 0.54
PLS - Logistic regression 0.70 0.65, 0.75 0.55
Penalized Logistic Regression 0.53 0.49, 0.58 0.50
Partial Least Squares 0.70 0.65, 0.75 0.55
PLS - Random Forest 0.67 0.63, 0.72 0.57
The table presents the results taking into consideration whether they were part of
CI of validation datasets WITH overlap with TCGA testing set CI: in red. CI of validat
under the ROC curve. CI: confidence intervals. SE: Standard Error. PAM: Prediction a
and selection operatorThe bulk of OVCA research is directed at understand-
ing the biology of the disease [5, 6] and defining subse-
quent treatment for those who do not respond or recur
after initial chemotherapy [16]. By comparison, we have
a very poor understanding of which patients are at risk
of failing initial treatment, due in large part to a lack of
validated biomarkers or molecular signatures that can
effectively predict chemo-response [7, 8]. Previous
attempts have been limited by the number of patients
included in the study, analysis of a mixture of histo-
logical types and stages, and lack of validation in inde-




95% CI AUC 95% CI AUC 95% CI
0.56, 0.71 0.61 0.50, 0.73 0.59 0.51, 0.67
0.50, 0.63 0.62 0.51, 0.73 0.53 0.50, 0.55
0.51, 0.63 0.64 0.53, 0.75 0.52 0.47, 0.57
0.50, 0.50 0.63 0.49, 0.76 0.50 0.50, 0.50
0.47, 0.60 0.59 0.48, 0.70 0.60 0.50, 0.69
0.48, 0.63 0.68 0.56, 0.80 0.61 0.51, 0.70
0.47, 0.52 0.54 0.48, 0.60 0.50 0.47, 0.53
0.48, 0.62 0.66 0.54, 0.78 0.61 0.51, 0.70
0.50, 0.64 0.62 0.53, 0.71 0.61 0.52, 0.71
the training or validation set
ion datasets with NO overlap with TCGA testing set CI: in green. AUC: area
nalysis for microarrays; PLS: Partial least squares; Lasso: least absolute shrinkage
Table 8 Validation of optimized 34-gene prediction models
ALL 34 GENES AVAILABLE
Training set Validation sets
TCGA: 34 genes Australia: 34 genes Ferriss: 34 genes MCC: 34 genes
AUC SE 95% CI AUC SE 95% CI AUC SE 95% CI AUC SE 95% CI
Random Forest 0.74 0.02 0.71, 0.77 0.72 0.01 0.69, 0.75 0.56 0.09 0.38, 0.73 0.57 0.04 0.48, 0.66
Lasso 0.66 0.02 0.61, 0.70 0.72 0.03 0.67, 0.78 0.57 0.06 0.44, 0.69 0.66 0.06 0.55, 0.77
Elastic Net 0.65 0.02 0.61, 0.69 0.72 0.03 0.66, 0.77 0.58 0.05 0.48, 0.68 0.66 0.06 0.54, 0.77
PAM 0.64 0.03 0.58, 0.69 0.72 0.04 0.63, 0.80 0.57 0.10 0.36, 0.77 0.45 0.05 0.36, 0.54
Diagonal Discriminant Analysis 0.74 0.02 0.71, 0.78 0.73 0.03 0.66, 0.79 0.55 0.07 0.40, 0.69 0.50 0.05 0.41, 0.60
PLS - Logistic regression 0.72 0.03 0.66, 0.77 0.72 0.01 0.69, 0.75 0.51 0.14 0.24, 0.78 0.64 0.07 0.50, 0.78
Penalized Logistic Regression 0.79 0.01 0.77, 0.81 0.70 0.02 0.67, 0.74 0.59 0.06 0.47, 0.71 0.66 0.06 0.55, 0.77
Partial Least Squares 0.71 0.03 0.66, 0.77 0.72 0.01 0.70, 0.75 0.54 0.13 0.29, 0.79 0.64 0.07 0.50, 0.78
PLS - Random Forest 0.74 0.01 0.71, 0.76 0.67 0.02 0.64, 0.71 0.59 0.13 0.34, 0.83 0.64 0.07 0.49, 0.78
The table presents the results taking into consideration whether they were part of the training or validation set
CI of validation datasets WITH overlap with TCGA testing set CI: in red. CI of validation datasets with NO overlap with TCGA testing set CI: in green. AUC: area
under the ROC curve. CI: confidence intervals. SE: Standard Error. PLS: Partial least squares
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associated glycoprotein of unknown function that is used
clinically to assess disease burden, though it has limited
value in predicting chemo-response [9, 10, 39]. In the
present study, we have created prediction models of
chemo-response from a 422-gene signature comprising
only serous cases, the most common type of OVCA.
These prediction models not only had AUCs over 70 %,
but were replicated and validated in the largest collec-
tion of independent serous OVCA databases available to
date.
Conclusions
One of the major strengths of this study is the replica-
tion and validation of prediction models in large inde-
pendent datasets containing gene expression specific to
serous OVCA and information about response to
chemotherapy. However, it is important to recognize the
limitations inherent in the retrospective design of the
databases used to create and validate the prediction
models, especially since these databases were not origin-
ally intended to study chemo-response as a primary out-
come variable. Although this clinical parameter was
recorded in all databases, it might contain biases. To
minimize this, we used a strict definition of chemo-
response to segregate patients into CR and IR. Regardless
of these limitations, we demonstrate replication and valid-
ation of both the 422-gene and the 34-gene models across
multiple databases, with overlapping CIs. Of particular sig-
nificance is the validation of the optimized 34-gene models
given the variability in gene expression analysis among
different datasets. This highlights the utility of this gene sig-
nature as a bona fide indicator of chemo-response.
Identification of characteristics independently associated
with misclassification could be very helpful in improving
prediction models. For example, if we identify that patients
with BMI > 50 are more likely to be misclassified, we might
exclude those patients from the prediction process to en-
hance the classification of the other patients. Also, based
on the observations made with patients with optimaltreatment, fine-tuning of the prediction models may be
possible, and perhaps necessary. Researchers in cardiovas-
cular disease have been at the forefront of developing risk
prediction equations utilizing clinical risk factors for the
prediction of cardiovascular events, as in the Framingham
Study [40]. Recently, new biomarkers and nonclinical mea-
sures have been studied to improve these risk prediction
tools in the population [41]. Adding new biomarkers to the
classic clinical risk factors may improve the model and offer
better prediction of the 15–20 % of patients with cardiovas-
cular events that have no clinical risks before the episode
[41]. In OVCA, we found that there was one variable asso-
ciated with misclassification, ‘optimal treatment’. Variables
associated with the adequate delivery of optimal treatment
in OVCA (surgery and chemotherapy) have the potential to
improve prediction models significantly [42]. Quantification
and different metrics for optimal treatment delivery could
be determined in a prospective set of patients with compre-
hensive clinical data collection in order to better under-
stand which factors influence treatment outcome.
A caveat to our study is that datasets with incomplete data
performed poorly, which was accentuated in models with 34
genes. For example, in the Yoshihara dataset [37], we only
lost expression information for one of the seven more influ-
ential genes in the model. However, this gene (MATK) was
ranked second in importance, so the model underper-
formed. The Bentink database [38] lost fewer genes that
Yoshihara (12 versus 14) but two of them were seven of the
most influential genes, and the performance was inferior to
the Yoshihara database. Trihn databse [36] lost four of the
seven most influential genes, including the first two (RHOT1
and MATK), with serious consequences for its performance.
Although this loss of performance could be seen as a prob-
lem for the construction of our prediction models, it also
underscores that the importance of the genes included in
the model is proportional to its performance, thereby sup-
porting the robust performance of the 34-gene prediction
models. Therefore, we propose that these prediction models
are very promising and are robust across different databases
and classifiers. Nevertheless, additional validation analyses
Gonzalez Bosquet et al. Molecular Cancer  (2016) 15:66 Page 13 of 15are necessary to test their utility as a clinical test for re-
sponse to chemotherapy in OVCA.
As to the pathways associated with the 422-gene signa-
ture, the majority of the 34 selected genes included in the
optimized prediction model are drawn from cellular func-
tions previously associated with response to chemotherapy
[8, 18]. Specifically, the pathway enrichment analysis iden-
tified pathways involved in DNA damage repair, replica-
tion, protein metabolism, cell cycle and apoptosis, as well
as cytoskeletal remodeling and cell adhesion functions, all
of which have been associated with cancer transformation
and proliferation [43]. Several genes in our optimized
model have potential implications relative to the etiology
or treatment of serous OVCA. For example, mutations in
DNA polymerase epsilon (POLE) have been reported in
endometrial and colon cancers with elevated numbers of
somatic mutations [44, 45], which appears to correlate
with a robust intratumoral T-cell response and better
prognosis [46]. To date, however, there have been no re-
ports of POLE differential gene expression and its associ-
ation with prognosis in serous OVCA. Decreased
expression of GCNT1 [47], DROSHA [48] and increased
expression of TIMP3 [49] have been associated with de-
creased PFS and OS in independent analyses of TCGA. Of
note, we found that POLE, LRRC3D, and TIMP3 muta-
tions were all associated with improved survival.
Other genes, like FAP, have been associated with clinical
resistance to chemotherapy in patients with serous
OVCA, which carries worse prognosis and survival [50].
Although there is no direct evidence of clinical association
with progression of disease in serous ovarian cancer, there
are in vitro studies that implicate NUAK1 (ARK5) with in-
vasion and progression in ovarian cancer cell lines [51].
ARK5 expression has been found to be elevated in serous
OVCA, and its expression has been associated with inva-
sion and metastasis in cancer in general [51]. Supporting
the role of NUAK1/ARK5 in the aggressive cancer pheno-
type, this gene was independently associated with de-
creased survival (HR = 1.34, 95 % CI 1.16–1.56).
We also identified two genes, thrombospondin I (THBS1)
and PDGFD, which participate in a wide range of signaling
pathways that regulate cellular processes involved in cancer
genesis and progression [52]. Thrombospondin I is a se-
creted protein that associates with the extracellular matrix
and possesses a variety of biologic functions, including hav-
ing potent antiangiogenic activity. In OVCA, decreased pro-
duction of thrombospondin I results in increased expression
of vascular endothelial growth factor (VEGF) and other an-
giogenic factors such as P1GF, FGF-2 and PDGFB [53].
PDGFD, also a member of the platelet-derived growth factor
(PDGF) family, participates in cytoskeletal remodeling and,
through its role in cell migration, contributes to vascular in-
tegrity and function mediated by perycite coverage of ves-
sels. This action could be disrupted in tumors [43]. Also,platelet levels during treatment and recruitment to tumors
have been associated with chemo-response [54]. Taken to-
gether, these data may provide a molecular basis for the effi-
cacy of bevacizumab, a humanized antibody against VEGF,
which has been shown to improve progression-free survival
and even overall survival in a subset of serous OVCA pa-
tients [55, 56], or the use of multitarget tyrosine kinase in-
hibitors to simultaneously block VEGFR, PDGFR and FGFR
pathways [57].
Up to a third of the patients undergoing treatment for ad-
vanced serous OVCA do not respond to treatment and have
a very poor prognosis. Indeed, more than 40 % of the pa-
tients in this poor prognosis group have had optimal ther-
apy, with optimal cytoreductive surgery and at least six
cycles of platinum-based chemotherapy, indicating that lack
of response is not due to incomplete clinical treatment.
Hence, for many such patients, the inherit characteristics of
the tumor appear to play a major role in lack of responsive-
ness. We have created 34-gene prediction models/classifiers
that consistently predict these patients approximately 80 %
of the time. This prediction model is specific for patients di-
agnosed with serous OVCA. Our ultimate goal is to create a
diagnostic tool that will predict each patient’s response to
chemotherapy. This is important, because, based on the po-
tential molecular targets identified in the 34-gene prediction
models, we could design clinical trials that compare stand-
ard therapy versus standard therapy in combination with
molecular agents targeting resistance pathways for the
women who are unlikely to respond to the usual upfront
regimens.Additional files
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